Epigenetic regulation of connective tissue growth factor by MicroRNA-214 delivery in exosomes from mouse or human hepatic stellate cells

Hepatology

Volumn 59, Issue 3, 2014, Pages 1118-1129

  Chen, Li ^a   Charrier, Alyssa ^a,b   Zhou, Yu ^a   Chen, Ruju ^a   Yu, Bo ^b,c   Agarwal, Kitty ^b   Tsukamoto, Hidekazu ^d,e   Lee, L James ^b,c   Paulaitis, Michael E ^b,c   Brigstock, David R ^a,b,f  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Ohio State University   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' (1,4 PHENYLENE)BIS[N [4 (4,5 DIHYDRO 1H IMIDAZOL 2 YL)PHENYL]ACRYLAMIDE]; ALCOHOL; CD9 ANTIGEN; CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; MICRORNA 214;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; BINDING SITE; CELL LYSATE; CELL SIZE; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; EPIGENETIC REPRESSION; EXOSOME; FATTY LIVER; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CULTURE; LIVER FIBROSIS; LUCIFERASE ASSAY; MEMBRANE VESICLE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN RNA BINDING; STELLATE CELL; UPREGULATION; WILD TYPE;

3' UNTRANSLATED REGIONS; ANILINE COMPOUNDS; ANIMALS; BENZYLIDENE COMPOUNDS; COCULTURE TECHNIQUES; CONNECTIVE TISSUE GROWTH FACTOR; DRUG-INDUCED LIVER INJURY; EPIGENESIS, GENETIC; EXOSOMES; HEP G2 CELLS; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; MICE; MICRORNAS; PRIMARY CELL CULTURE; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84896716487     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26768     Document Type: Article

References (31)

1. Friedman SL. Hepatic fibrosis - overview. Toxicology 2008;254:120-129.
2. Ghiassi-Nejad Z, Friedman SL. Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol 2008;2:803-816.
3. Brigstock DR, Goldschmeding R, Katsube KI, Lam SC, Lau LF, Lyons K, et al. Proposal for a unified CCN nomenclature. Mol Pathol 2003;56:127-128.
4. Huang G, Brigstock DR. Regulation of hepatic stellate cells by connective tissue growth factor. Front Biosci 2012;17:2495-2507.
5. Abou-Shady M, Friess H, Zimmermann A, di Mola FF, Guo XZ, Baer HU, et al. Connective tissue growth factor in human liver cirrhosis. Liver 2000;20:296-304.
6. Hora C, Negro F, Leandro G, Oneta CM, Rubbia-Brandt L, Muellhaupt B, et al. Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver Int 2008;28:370-376.
7. Kobayashi H, Hayashi N, Hayashi K, Yamataka A, Lane GJ, Miyano T. Connective tissue growth factor and progressive fibrosis in biliary atresia. Pediatr Surg Int 2005;21:12-16.
8. Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003;26:1-9.
9. Williams EJ, Gaca MD, Brigstock DR, Arthur MJ, Benyon RC. Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 2000;32:754-761.
10. Paradis V, Dargere D, Vidaud M, De Gouville AC, Huet S, Martinez V, et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999;30:968-976.
11. Chen L, Charrier AL, Leask A, French SW, Brigstock DR. Ethanol-stimulated differentiated functions of human or mouse hepatic stellate cells are mediated by connective tissue growth factor. J Hepatol 2011;55:399-406.
12. Brigstock DR. Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): from pharmacological inhibition in vitro to targeted siRNA therapy in vivo. J Cell Commun Signal 2009;3:5-18.
13. Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 2012;5 Suppl 1:S24.
14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
15. Dolganiuc A, Petrasek J, Kodys K, Catalano D, Mandrekar P, Velayudham A, et al. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res 2009;33:1704-1710.
16. Chairoungdua A, Smith DL, Pochard P, Hull M, Caplan MJ. Exosome release of beta-catenin: a novel mechanism that antagonizes Wnt signaling. J Cell Biol 2010;190:1079-1091.
17. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010;285:17442-17452.
18. Noetel A, Kwiecinski M, Elfimova N, Huang J, Odenthal M. microRNA are central players in anti- and profibrotic gene regulation during liver fibrosis. Front Physiol 2012;3:49.
19. Loebel DA, Tsoi B, Wong N, Tam PP. A conserved noncoding intronic transcript at the mouse Dnm3 locus. Genomics 2005;85:782-789.
20. Iizuka M, Ogawa T, Enomoto M, Motoyama H, Yoshizato K, Ikeda K, et al. Induction of microRNA-214-5p in human and rodent liver fibrosis. Fibrogenesis Tissue Repair 2012;5:12.
21. Thery C. Exosomes: secreted vesicles and intercellular communications. F1000 Biol Rep 2011;3:15.
22. Masyuk AI, Huang BQ, Ward CJ, Gradilone SA, Banales JM, Masyuk TV, et al. Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. Am J Physiol Gastrointest Liver Physiol 2010;299:G990-999.
23. Kogure T, Lin WL, Yan IK, Braconi C, Patel T. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 2011;54:1237-1248.
24. Pan Q, Ramakrishnaiah V, Henry S, Fouraschen S, de Ruiter PE, Kwekkeboom J, et al. Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut 2012;61:1330-1339.
25. Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol 2012;9:850-859.
26. Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011;6:e26971.
27. Starkey Lewis PJ, Merz M, Couttet P, Grenet O, Dear J, Antoine DJ, et al. Serum microRNA biomarkers for drug-induced liver injury. Clin Pharmacol Ther 2012;92:291-293.
28. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012;56:167-175.
29. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-142.
30. Zahm AM, Hand NJ, Boateng LA, Friedman JR. Circulating microRNA is a biomarker of biliary atresia. J Pediatr Gastroenterol Nutr 2012;55:366-369.
31. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011;53:209-218.